Effects of the expression of serum SIRT1 on therapeutic efficacy of sodium valproate in the treatment of epilepsy patients
- VernacularTitle:血清SIRT1表达对丙戊酸钠治疗癫痫患者疗效的影响
- Author:
Yanping YANG
1
;
Die HE
1
;
Zhen ZHOU
1
,
2
;
Qingfan ZENG
3
;
Hongying PENG
4
;
Lixin ZHAO
5
;
Dan MA
6
Author Information
1. Dept. of Pharmacy，the Affiliated Baiyun Hospital of Guizhou Medical University，Guiyang 550014，China
2. Dept. of Pharmacy，the Affiliated Hospital of Guizhou Medical University，Guiyang 550004，China
3. Dept. of Anesthesiology，the Affiliated Baiyun Hospital of Guizhou Medical University，Guiyang 550014，China
4. Dept. of Nephrology，the Affiliated Baiyun Hospital of Guizhou Medical University，Guiyang 550014，China
5. Dept. of Traditional Chinese Medicine，the Affiliated Baiyun Hospital of Guizhou Medical University，Guiyang 550014，China
6. Dept. of Hematology，the Affiliated Hospital of Guizhou Medical University，Guiyang 550004，China
- Publication Type:Journal Article
- Keywords:
Sirtuin-1;
epilepsy;
sodium valproate;
blood concentration monitoring;
liver function
- From:
China Pharmacy
2022;33(23):2886-2890
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the effects of the expression of serum Sirtuin-1 （SIRT1） on therapeutic efficacy of sodium valproate （VPA） in the treatment of epilepsy patients. METHODS Fifty-four epileptic patients were collected from the Affiliated Baiyun Hospital of Guizhou Medical University from Mar. to Oct. 2021 as the research objects， and fifty healthy people were also collected during corresponding period as baseline reference samples. The patients whose relative mRNA expression of SIRT1 was lower than the baseline were selected as SIRT1 low-expression treatment group， and the patients whose that expression was higher than the baseline as SIRT1 high-expression treatment group.All patients were treated with low dose （12 mg/kg or about 600 mg/day） of VPA for 3 months， and the clinical efficacy was evaluated. The dosage of VPA in patients with ineffective gzwkj2021-468） epilepsy control should be increased to 15 mg/kg or about 800 mg/day for another 3 months as SIRT1 high-expression intensive treatment group and SIRT1 low-expression intensive treatment group. Clinical efficacies were evaluated. The blood concentration and liver function indexes of the patients were detected after 3 months of treatment and 3 months of intensive treatment. RESULTS Before treatment， among 54 epileptic patients， 31 epileptic patients had low expression of SIRT1， and 23 had high expression of SIRT1. After 3 months of low-dose VPA treatment， within effective blood concentration of VPA， effective control rate of patients in SIRT1 high-expression treatment group was significantly lower than SIRT1 low-expression treatment group （P＜0.05）. After 3 months of intensive treatment， the effective control rate of patients SIRT1 high-expression intensive treatment group was significantly higher than SIRT1 high expression treatment group （P＜0.05）. No abnormality was found in liver function indexes during VPA treatment. CONCLUSIONS Epilepsy in patients with high expression of serum SIRT1 may be more difficult to control when VPA is within the effective blood concentration range； when the VPA dose is effectively increased， the effective control rate of epilepsy can be improved.
